What is the pivotal weight-loss trial for tirzepatide?

SURMOUNT-1 (NEJM 2022, n=2,539, PMID 35658024). Adults without diabetes and BMI ≥30 (or ≥27 with comorbidity) achieved 22.5% mean weight loss at 15 mg over 72 weeks vs 2.4% on placebo.

How does tirzepatide compare to semaglutide in trials?

SURPASS-2 (NEJM 2021, PMID 34170647) was the head-to-head trial. Tirzepatide produced approximately 47% greater weight loss than semaglutide 1 mg, with superior HbA1c reduction in adults with type 2 diabetes.

What was SURMOUNT-OSA?

SURMOUNT-OSA evaluated tirzepatide for obstructive sleep apnea in obesity. Results led to Zepbound's FDA approval for moderate-to-severe OSA in adults with obesity (December 2024).

What are the major contraindications?

Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy, and breastfeeding. Boxed warning addresses thyroid C-cell tumors observed in rodent studies.

Tirzepatide Clinical Research

The Clinical Evidence Behind Tirzepatide

NexLife

★★★★★ 4.7 (Trustpilot aggregate · verify on Trustpilot)

✨ Editor's Pick · 94/100 💊 Compounded semaglutide + tirzepatide 👨‍⚕️ MD/DO-supervised 🏥 503A & 503B pharmacies 🧪 Labs included 📍 Nationwide (subject to licensure) ✓ LegitScript-certified 💰 Flat-rate, dose-independent 🔁 Care360 coaching 📱 Apple Health / Google Fit sync

$186 / month*

*12-month plan · flat rate across full 2.5–15 mg titration.
$190 (6-mo) · $195 (3-mo) · $215 (month-to-month).

Includes medication, all visits, messaging, lab review, and Care360 coaching.

Visit NexLife →

Or call (949) 818-8000

Trade-offs to know

Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.

Mechanism of dual GLP-1/GIP receptor agonism, pivotal SURMOUNT and SURPASS trial data, and emerging cardiovascular and renal outcomes — sourced from peer-reviewed publications.

Researched By

Dr. Parmis

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Adam Kennah, M.D.

Board-Certified Physician

Last clinically reviewed: May 15, 2026 · This page is informational and does not constitute medical advice.

Mechanism of action — Dual incretin receptor agonism

Tirzepatide is the first dual GLP-1/GIP receptor agonist approved for clinical use. The two incretins activated by tirzepatide function complementarily:

GLP-1 (glucagon-like peptide-1): Secreted by intestinal L-cells. Reduces appetite via central nervous system signaling, delays gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon.
GIP (glucose-dependent insulinotropic polypeptide): Secreted by intestinal K-cells. Synergistic effects on insulin secretion, additional preferential effects on adipose tissue insulin sensitivity, modest contributions to energy expenditure.

The dual mechanism explains the magnitude of weight loss observed with tirzepatide vs single-receptor GLP-1 agonists like semaglutide.

SURMOUNT trial program — Tirzepatide for chronic weight management

SURMOUNT-1 (Pivotal weight loss trial in adults without diabetes)

Jastreboff AM, et al., NEJM 2022. n=2,539 adults with BMI ≥30 or BMI ≥27 with comorbidity. 72-week trial. Mean weight loss at 72 weeks: 15.0% (5 mg), 19.5% (10 mg), 22.5% (15 mg), vs 2.4% (placebo). PMID: 35658024.

SURMOUNT-2 (Tirzepatide in T2 diabetes)

Garvey WT, et al., Lancet 2023. n=938 adults with T2D and obesity. Confirmed efficacy in patients with diabetes.

SURMOUNT-3 (With intensive lifestyle intervention)

Wadden TA, et al., Nat Med 2023. Tirzepatide combined with intensive behavioral therapy. Demonstrated additive effect.

SURMOUNT-4 (Maintenance after initial weight loss)

Aronne LJ, et al., JAMA 2024. Tirzepatide continuation vs withdrawal. Sustained weight maintenance with continued therapy and significant weight regain with withdrawal.

SURPASS trial program — Tirzepatide for T2 diabetes

SURPASS-2 (Head-to-head with semaglutide)

Frías JP, et al., NEJM 2021. n=1,879 adults with T2D. Tirzepatide demonstrated superior glycemic control AND ~47% greater weight loss at all doses vs semaglutide. PMID: 34170647.

SURPASS-CVOT (Cardiovascular outcomes — in progress)

Ongoing trial evaluating tirzepatide cardiovascular outcomes vs dulaglutide in patients with T2D and established CV disease. Results expected 2026-2027.

Compounded tirzepatide — pharmacy quality standards

USP <797> — sterile compounding standards including environmental controls, personnel training, beyond-use dating
USP <71> — sterility testing
USP <85> — bacterial endotoxin testing
FDA cGMP (21 CFR 211) — applies to 503B outsourcing facilities

NexLife discloses adherence to all the above; many competitors do not.

Side effect profile

Most common adverse events from SURMOUNT-1 and SURPASS trials:

Nausea — 25-31%
Diarrhea — 19-23%
Decreased appetite — 9-11%
Vomiting — 8-12%
Constipation — 6-10%

Boxed warnings & contraindications

Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors (rodent studies). Contraindicated in:

Personal or family history of medullary thyroid carcinoma (MTC)
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy and breastfeeding
Severe gastroparesis (use with caution)
History of pancreatitis (use with caution)

For deeper clinical resources, see clinical research index.